var data={"title":"Rifaximin: Pediatric drug information","body":"<div id=\"topicContent\" class=\"utdArticleSection utdStyle\"><div id=\"drugTitle\">Rifaximin: Pediatric drug information</div><div id=\"lexiTitleImg\"></div><div class=\"clear\"></div><div id=\"lcoSearchClickUrl\"><a href=\"http://online.lexi.com/lco/action/api/find/globalid/6915?utd=1\" target=\"_blank\">Access Lexicomp Online here.</a></div><div id=\"drugCopy\">Copyright 1978-2018 Lexicomp, Inc. All rights reserved.</div><div id=\"topicText\">(For additional information <a href=\"topic.htm?path=rifaximin-drug-information\" class=\"drug drug_general\">see &quot;Rifaximin: Drug information&quot;</a> and <a href=\"topic.htm?path=rifaximin-patient-drug-information\" class=\"drug drug_patient\">see &quot;Rifaximin: Patient drug information&quot;</a>)<br></br>For abbreviations and symbols that may be used in Lexicomp (<a href=\"image.htm?imageKey=DRUG%2F57469\" class=\"graphic graphic_table\">show table</a>)<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F218514\" class=\"list ubnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: US</span>\n    <ul>\n      <li>Xifaxan</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F48898244\" class=\"list cbnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: Canada</span>\n    <ul>\n      <li>Zaxine</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F1034823\" class=\"list_set htclist drugH1Div drugBrandNames\"><span class=\"drugH1\">Therapeutic Category</span>\n    <ul>\n      <li>\n        <span class=\"list-set-name\">Antibiotic, Miscellaneous</span></li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F1034851\" class=\"block dos drugH1Div\"><span class=\"drugH1\">Dosing: Usual</span><p>(For additional information <a href=\"topic.htm?path=rifaximin-drug-information\" class=\"drug drug_general\">see &quot;Rifaximin: Drug information&quot;</a>)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Pediatric:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Diarrhea, travelers&rsquo;:</b> Oral: <b>Note:</b> Efficacy has not been established for the treatment of diarrhea due to pathogens other than <i>E. coli</i>, including <i>C. jejuni</i>, <i>Shigella</i>, and <i>Salmonella</i>; avoid use in diarrhea with fever or blood in the stool; consider alternative therapy if symptoms persist or worsen after 24 to 48 hours of treatment </p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Children 3 to 11 years: Limited data available: 100 mg 4 times daily for up to 5 days has been used in 38 children (age range: 3 to 8 years) to treat infectious diarrhea (Beseghi 1998; Frisari 1997)</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Children &ge;12 years and Adolescents: 200 mg 3 times daily for 3 days</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Hepatic encephalopathy:</b> Oral: Adolescents &ge;18 years: Reduction of overt hepatic encephalopathy recurrence: 550 mg 2 times daily</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Inflammatory bowel disease (IBD) (Crohn disease, ulcerative colitis):</b> Limited data available: Oral: Children &ge;8 years and Adolescents: 10 to 30 mg/kg/day in divided doses; maximum daily dose: 1200 mg/<b>day</b>. Dosing based on a retrospective experience of 23 pediatric patients (age range: 8 to 21 years) with IBD flare (Crohn disease, n=12; ulcerative colitis: n=11); patients received rifaximin 400 to 1200 mg/day (10 to 30 mg/kg/day); improvements in diarrhea and abdominal pain were reported within the first 4 weeks of therapy for the majority of patients (~74%), and within a week in some cases; higher total daily doses (1200 mg/day vs 400 mg/day) were associated with better symptom control (Muniyappa 2009). </p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Small intestinal bacterial overgrowth (SIBO) [eg, irritable bowel syndrome (IBS), chronic abdominal pain]:</b> Limited data available; efficacy results variable: Oral: Children &ge;3 years and Adolescents: 200 mg 3 times daily, dosing based on prospective study of 50 pediatric patients with IBS (age range: 3 to 15 years); results showed 7 days of therapy resulted in improved symptoms and a reduction in bacterial overgrowth based on lactulose breath test (LBT) results (Scarpellini 2013); however, a double-blind placebo-controlled trial in pediatric patients (n=75 including 49 who received rifaximin, age range: 8 to 18 years) with chronic abdominal pain showed very low efficacy in normalizing LBT (20% response rate) and treating SIBO compared to placebo at a higher dose of 550 mg 3 times daily for 7 days (Collins 2011). </p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Adults:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Hepatic encephalopathy:</b> Oral: Reduction of overt hepatic encephalopathy recurrence: 550 mg 2 times daily</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Travelers' diarrhea:</b> Oral: 200 mg 3 times daily for 3 days </p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Dosing adjustment for renal impairment:</b> There are no dosage adjustments provided in the manufacturer's labeling (has not been studied).</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Dosing adjustment for hepatic impairment:</b> No dosage adjustment necessary. Use with caution in patients with severe impairment (Child-Pugh class C) as systemic absorption does occur and pharmacokinetic parameters are highly variable.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F218495\" class=\"block foc drugH1Div\"><span class=\"drugH1\">Dosage Forms</span>\n    <p style=\"text-indent:0em;text-align:justify;display:inline\">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Tablet, Oral: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Xifaxan: 200 mg [contains edetate disodium]</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Xifaxan: 550 mg</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F218483\" class=\"block geq drugH1Div\"><span class=\"drugH1\">Generic Availability (US)</span>\n    <p style=\"text-indent:0em;display:inline\">No</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F1034856\" class=\"block adm drugH1Div\"><span class=\"drugH1\">Administration</span>\n    <p style=\"text-indent:0em;display:inline\">Oral: May be administered with or without food. </p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F218511\" class=\"block sts drugH1Div\"><span class=\"drugH1\">Storage/Stability</span>\n    <p style=\"text-indent:0em;display:inline\">Store at 20&deg;C to 25&deg;C (68&deg;F to 77&deg;F); excursions permitted to 15&deg;C to 30&deg;C (59&deg;F to 86&deg;F).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F1034824\" class=\"block use drugH1Div\"><span class=\"drugH1\">Use</span>\n    <p style=\"text-indent:0em;display:inline\">Treatment of travelers' diarrhea caused by noninvasive strains of <i>E. coli</i> (FDA approved in ages &ge;12 years and adults); reduction in the risk of overt hepatic encephalopathy (HE) recurrence (FDA approved in ages &ge;18 years and adults); has also been used in inflammatory bowel disease and irritable bowel syndrome</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F803022\" class=\"block mst drugH1Div\"><span class=\"drugH1\">Medication Safety Issues</span>\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">Sound-alike/look-alike issues: </span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:-2em;margin-left:4em;\">RifAXIMin may be confused with rifAMPin</p></div>\r\n</div>\r\n</div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F218535\" class=\"block arm drugH1Div\"><span class=\"drugH1\">Adverse Reactions</span>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Cardiovascular: Peripheral edema</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Central nervous system: Depression, dizziness, fatigue, headache</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Dermatological: Pruritus, skin rash</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Gastrointestinal: Abdominal pain, nausea, pseudomembranous colitis</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Hematologic &amp; oncologic: Anemia</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Hepatic: Ascites, increased serum ALT</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Neuromuscular &amp; skeletal: Arthralgia, increased creatine phosphokinase, muscle spasm</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Respiratory: Dyspnea, epistaxis, nasopharyngitis</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Miscellaneous: Fever</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>All indications:</b> Rare but important or life-threatening: Anaphylaxis, <i>Clostridium difficile</i> associated diarrhea, exfoliative dermatitis, hypersensitivity reaction</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F218501\" class=\"block coi drugH1Div\"><span class=\"drugH1\">Contraindications</span>\n    <p style=\"text-indent:0em;display:inline\">Hypersensitivity to rifaximin, other rifamycin antibiotics, or any component of the formulation</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F218485\" class=\"block war drugH1Div\"><span class=\"drugH1\">Warnings/Precautions</span>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>\n        <i>Concerns related to adverse effects:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Hypersensitivity: Hypersensitivity reactions (eg, exfoliative dermatitis, rash, urticaria, flushing, angioneurotic edema, pruritus, anaphylaxis) have occurred; these events have occurred as early as within 15 minutes of drug administration.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Superinfection: Prolonged use may result in fungal or bacterial superinfection, including <i>C. difficile</i>-associated diarrhea (CDAD) and pseudomembranous colitis; CDAD has been observed &gt;2 months postantibiotic treatment.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>\n        <i>Disease-related concerns:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Diarrhea: Appropriate use: Avoid use in diarrhea with fever and/or blood in the stool and in the treatment of diarrhea due to pathogens other than <i>E. coli</i>, including <i>C. jejuni</i>, <i>Shigella</i>, and <i>Salmonella</i> (efficacy has not been established). Consider alternative therapy if symptoms persist or worsen after 24 to 48 hours of treatment.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Hepatic impairment: Efficacy for prevention of encephalopathy has not been established in patients with a Model for End-Stage Liver Disease (MELD) score &gt;25; use caution in patients with severe hepatic impairment (Child-Pugh class C).</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>\n        <i>Concurrent drug therapy issues:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Drug-drug interactions: Potentially significant interactions may exist, requiring dose or frequency adjustment, additional monitoring, and/or selection of alternative therapy. Consult drug interactions database for more detailed information.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>\n        <i>Dosage form specific issues:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Propylene glycol: Some dosage forms may contain propylene glycol; large amounts are potentially toxic and have been associated hyperosmolality, lactic acidosis, seizures, and respiratory depression; use caution (AAP 1997; Zar 2007).</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>\n        <i>Other warnings/precautions:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Appropriate use: Not for treatment of systemic infections; &lt;1% is absorbed orally.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F218525\" class=\"block cyt drugH1Div\"><span class=\"drugH1\">Metabolism/Transport Effects</span>\n    <p style=\"text-indent:0em;display:inline\">\n      <b>Substrate</b> of CYP3A4 (minor), OATP1A2/SLCO1A2, OATP1B1/SLCO1B1, OATP1B3/SLCO1B3, P-glycoprotein/ABCB1; <b>Note:</b> Assignment of Major/Minor substrate status based on clinically relevant drug interaction potential; <b>Inhibits</b> OATP1A2/SLCO1A2, OATP1B1/SLCO1B1, OATP1B3/SLCO1B3</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F218489\" class=\"block dri drugH1Div\"><span class=\"drugH1\">Drug Interactions</span>\n    <br/><br/><div id=\"lexiInteractAddInfo\" class=\"lexi\">(For additional information: <a href=\"https://www.uptodate.com/drug-interactions/?search=&amp;topicId=94528&amp;source=responsive_topic\" class=\"dip\" target=\"_blank\">Launch drug interactions program</a>)</div><div id=\"lexiInteractImgB\" class=\"lexi\"><img src=\"/images/lexiComp/Lexicomp_2012_71x17.gif\" width=\"71\" height=\"17\" border=\"0\"/></div><div class=\"clear\"></div><p style=\"text-indent:-2em;margin-left:2em;\">BCG (Intravesical): Antibiotics may diminish the therapeutic effect of BCG (Intravesical). <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">BCG Vaccine (Immunization): Antibiotics may diminish the therapeutic effect of BCG Vaccine (Immunization). <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">CycloSPORINE (Systemic): May increase the serum concentration of RifAXIMin.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Lactobacillus and Estriol: Antibiotics may diminish the therapeutic effect of Lactobacillus and Estriol. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">P-glycoprotein/ABCB1 Inhibitors: May increase the serum concentration of RifAXIMin.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Sodium Picosulfate: Antibiotics may diminish the therapeutic effect of Sodium Picosulfate.  Management: Consider using an alternative product for bowel cleansing prior to a colonoscopy in patients who have recently used or are concurrently using an antibiotic.<i> Risk D: Consider therapy modification</i></p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F218503\" class=\"block pri drugH1Div\"><span class=\"drugH1\">Pregnancy Implications</span>\n    <p style=\"text-indent:0em;display:inline\">Adverse events have been observed in some animal reproduction studies. Due to the limited oral absorption of rifaximin in patients with normal hepatic function, exposure to the fetus is expected to be low. </p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F1034858\" class=\"block mop drugH1Div\"><span class=\"drugH1\">Monitoring Parameters</span>\n    <p style=\"text-indent:0em;display:inline\">Temperature, blood in stool, change in symptoms; monitor changes in mental status in hepatic encephalopathy </p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F218484\" class=\"block pha drugH1Div\"><span class=\"drugH1\">Mechanism of Action</span>\n    <p style=\"text-indent:0em;display:inline\">Rifaximin inhibits bacterial RNA synthesis by binding to bacterial DNA-dependent RNA polymerase.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F218500\" class=\"block phk drugH1Div\"><span class=\"drugH1\">Pharmacodynamics/Kinetics (Adult data unless noted)</span>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Absorption: Oral: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Traveler's diarrhea: Low</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Hepatic encephalopathy: Increased absorption in patients with Child-Pugh class C compared with patients with Child-Pugh class A</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Protein binding: Healthy subjects: 67.5%; Hepatic impairment: 62%</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Metabolism: Extensive, mainly by CYP3A</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Half-life elimination: Healthy subjects: 5.6 hours; IBS-D patients: 6 hours </p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Time to peak: Healthy subjects and ISB-D patients: ~1 hour</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Excretion: Feces (96.6%; primarily as unchanged drug); urine (0.32%)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F10806437\" class=\"block exp drugH1Div\"><span class=\"drugH1\">Extemporaneous Preparations</span>\n    <p style=\"text-indent:0em;display:inline\">A 20 mg/mL oral suspension may be made using tablets. Crush six 200 mg tablets and reduce to a fine powder. Add 30 mL of a 1:1 mixture of Ora-Sweet&reg; and Ora-Plus&reg; or a 1:1 mixture of Ora-Sweet&reg; SF and Ora-Plus&reg;; mix well while adding the vehicle in geometric proportions to <b>almost</b> 60 mL; transfer to a calibrated bottle, rinse mortar with vehicle, and add quantity of vehicle sufficient to make 60 mL. Label &quot;shake well&quot;. Stable 60 days at room temperature.</p>\n    <div class=\"reference\">Cober MP, Johnson CE, Lee J, et al, &quot;Stability of Extemporaneously Prepared Rifaximin Oral Suspensions,&quot; <i>Am J Health Syst Pharm</i>, 2010, 67(4):287-89.<span class=\"pubmed-id\">20133533</span></div>\r\n</div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F218502\" class=\"block fee drugH1Div\"><span class=\"drugH1\">Pricing: US</span>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Tablets</b> (Xifaxan Oral)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">200 mg (30): $667.58</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">550 mg (60): $2,545.01</p>\n    <p style=\"text-indent:0em;\">\n      <b>Disclaimer: </b>A representative AWP (Average Wholesale Price) price or price range is provided as reference price only. A range is provided when more than one manufacturer's AWP price is available and uses the low and high price reported by the manufacturers to determine the range. The pricing data should be used for benchmarking purposes only, and as such should not be used alone to set or adjudicate any prices for reimbursement or purchasing functions or considered to be an exact price for a single product and/or manufacturer.  Medi-Span expressly disclaims all warranties of any kind or nature, whether express or implied, and assumes no liability with respect to accuracy of price or price range data published in its solutions.  In no event shall Medi-Span be liable for special, indirect, incidental, or consequential damages arising from use of price or price range data.  Pricing data is updated monthly.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F5539924\" class=\"list fbnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: International</span>\n    <ul>\n      <li>Aximin (BD);</li>\n      <li>Bang Yi (CN);</li>\n      <li>Colidimin (AT);</li>\n      <li>Coloximina (AR);</li>\n      <li>Faxinorm (DK);</li>\n      <li>Flonorm (CO, CR, DO, GT, HN, MX, NI, PA, SV);</li>\n      <li>Henlix (BD);</li>\n      <li>Ifaxim (CO);</li>\n      <li>Lormyx (GR, IL);</li>\n      <li>Normiks (UA);</li>\n      <li>Normix (AR, BG, CL, CZ, HN, IT, KR, LB, PH, SK, TR, VN);</li>\n      <li>Qian Er Fen (CN);</li>\n      <li>Refero (HK, PT);</li>\n      <li>Rifadom (AR);</li>\n      <li>Rifatime (IN);</li>\n      <li>Rifax (BD);</li>\n      <li>Rifaxin (BD);</li>\n      <li>Rifxima (JP);</li>\n      <li>Spiraxin (ES);</li>\n      <li>Targaxan (GB, IE);</li>\n      <li>Tixtar (ES);</li>\n      <li>Tixteller (NL);</li>\n      <li>Tixtetller (ES);</li>\n      <li>Xifamin (BD);</li>\n      <li>Xifaxan (AU, BB, DE, HK, NL, NO, NZ, PL, SG);</li>\n      <li>Xifaxanta (GB)</li></ul></div>\r\n</div><div id=\"topicAgreement\">Use of UpToDate is subject to the <a href=\"https://www.uptodate.com/legal/license\" class=\"licenseLink\" id=\"sla_in_page\">Subscription and License Agreement</a>.</div><div id=\"references\" class=\"headingAnchor\"><h1>REFERENCES</h1><ol id=\"reference\">\r\n<li>\r\n<div class=\"reference\">\n    American Academy of Pediatrics Committee on Drugs. &quot;Inactive&quot; ingredients in pharmaceutical products: update (subject review). <i>Pediatrics</i>. 1997;99(2):268-278.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/rifaximin-pediatric-drug-information/abstract-text/9024461/pubmed\" target=\"_blank\" id=\"9024461\">9024461</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Beseghi U, De&rsquo;Angelis GL. Comparison of two non-absorbable antibiotics for treatment of bacterial enteritis in children. <i>Eur Rev Med Pharmacol Sci</i>. 1998;2(3-4):131-136.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/rifaximin-pediatric-drug-information/abstract-text/10546408/pubmed\" target=\"_blank\" id=\"10546408\">10546408</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Collins BS, Lin HC. Double-blind, placebo-controlled antibiotic treatment study of small intestinal bacterial overgrowth in children with chronic abdominal pain. <i>J Pediatr Gastroenterol Nutr</i>. 2011;52:382-386.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/rifaximin-pediatric-drug-information/abstract-text/21240023/pubmed\" target=\"_blank\" id=\"21240023\">21240023</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Frisari L, Viggiano V, Pelagalli M. An open, controlled study of two non-absorbable antibiotics for the oral treatment of paediatric infectious diarrhea. <i>Current Medical Research and Opinion</i>. 1997;14(1):39-45.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/rifaximin-pediatric-drug-information/abstract-text/9524792/pubmed\" target=\"_blank\" id=\"9524792\">9524792</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Muniyappa P, Gulati R, Mohr F, Hupertz V. Use and safety of rifaximin in children with inflammatory bowel disease. <i>Journal of Pediatric Gastroenterology and Nutrition</i>. 2009;49:400-404.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/rifaximin-pediatric-drug-information/abstract-text/19668011/pubmed\" target=\"_blank\" id=\"19668011\">19668011</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Scarpellini E, Giorgio V, Gabrielli M, et al. Rifaximin treatment for small intestinal bacterial overgrowth in children with irritable bowel syndrome: a preliminary study. <i>European Review for Medical and Pharmacological Sciences</i>. 2013;17:1314-1320.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/rifaximin-pediatric-drug-information/abstract-text/23740443/pubmed\" target=\"_blank\" id=\"23740443\">23740443</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Shehab N, Lewis CL, Streetman DD, Donn SM. Exposure to the pharmaceutical excipients benzyl alcohol and propylene glycol among critically ill neonates. <i>Pediatr Crit Care Med</i>. 2009;10(2):256-259.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/rifaximin-pediatric-drug-information/abstract-text/19188870/pubmed\" target=\"_blank\" id=\"19188870\">19188870</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Zar T, Graeber C, Perazella MA. Recognition, treatment, and prevention of propylene glycol toxicity. <i>Semin Dial</i>. 2007;20(3):217-219.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/rifaximin-pediatric-drug-information/abstract-text/17555487 /pubmed\" target=\"_blank\" id=\"17555487 \">17555487 </a>]</span></div>\r\n</li></ol></div><div id=\"topicVersionRevision\">Topic 94528 Version 70.0</div></div>","outline":"<div id=\"outlineSections\"><h2>Topic Outline</h2><ul><li class=\"plainItem\"><a sectionName=\"Brand Names: US\" href=\"#F218514\" class=\"outlineLink\">Brand Names: US</a></li><li class=\"plainItem\"><a sectionName=\"Brand Names: Canada\" href=\"#F48898244\" class=\"outlineLink\">Brand Names: Canada</a></li><li class=\"plainItem\"><a sectionName=\"Therapeutic Category\" href=\"#F1034823\" class=\"outlineLink\">Therapeutic Category</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Usual\" href=\"#F1034851\" class=\"outlineLink\">Dosing: Usual</a></li><li class=\"plainItem\"><a sectionName=\"Dosage Forms\" href=\"#F218495\" class=\"outlineLink\">Dosage Forms</a></li><li class=\"plainItem\"><a sectionName=\"Generic Availability (US)\" href=\"#F218483\" class=\"outlineLink\">Generic Availability (US)</a></li><li class=\"plainItem\"><a sectionName=\"Administration\" href=\"#F1034856\" class=\"outlineLink\">Administration</a></li><li class=\"plainItem\"><a sectionName=\"Storage/Stability\" href=\"#F218511\" class=\"outlineLink\">Storage/Stability</a></li><li class=\"plainItem\"><a sectionName=\"Use\" href=\"#F1034824\" class=\"outlineLink\">Use</a></li><li class=\"plainItem\"><a sectionName=\"Medication Safety Issues\" href=\"#F803022\" class=\"outlineLink\">Medication Safety Issues</a></li><li class=\"plainItem\"><a sectionName=\"Adverse Reactions\" href=\"#F218535\" class=\"outlineLink\">Adverse Reactions</a></li><li class=\"plainItem\"><a sectionName=\"Contraindications\" href=\"#F218501\" class=\"outlineLink\">Contraindications</a></li><li class=\"plainItem\"><a sectionName=\"Warnings/Precautions\" href=\"#F218485\" class=\"outlineLink\">Warnings/Precautions</a></li><li class=\"plainItem\"><a sectionName=\"Metabolism/Transport Effects\" href=\"#F218525\" class=\"outlineLink\">Metabolism/Transport Effects</a></li><li class=\"plainItem\"><a sectionName=\"Drug Interactions\" href=\"#F218489\" class=\"outlineLink\">Drug Interactions</a></li><li class=\"plainItem\"><a sectionName=\"Pregnancy Implications\" href=\"#F218503\" class=\"outlineLink\">Pregnancy Implications</a></li><li class=\"plainItem\"><a sectionName=\"Monitoring Parameters\" href=\"#F1034858\" class=\"outlineLink\">Monitoring Parameters</a></li><li class=\"plainItem\"><a sectionName=\"Mechanism of Action\" href=\"#F218484\" class=\"outlineLink\">Mechanism of Action</a></li><li class=\"plainItem\"><a sectionName=\"Pharmacodynamics/Kinetics (Adult data unless noted)\" href=\"#F218500\" class=\"outlineLink\">Pharmacodynamics/Kinetics (Adult data unless noted)</a></li><li class=\"plainItem\"><a sectionName=\"Extemporaneous Preparations\" href=\"#F10806437\" class=\"outlineLink\">Extemporaneous Preparations</a></li><li class=\"plainItem\"><a sectionName=\"Pricing: US\" href=\"#F218502\" class=\"outlineLink\">Pricing: US</a></li><li class=\"plainItem\"><a sectionName=\"Brand Names: International\" href=\"#F5539924\" class=\"outlineLink\">Brand Names: International</a></li><li class=\"plainItem\"><a href=\"#references\">REFERENCES</a></li></ul></div><div><h2>GRAPHICS <a href=\"#\" id=\"viewAllGraphicsLink\">View All</a></h2><div id=\"outlineGraphics\"><ul><li><div id=\"DRUG_PED/94528|TAB\" class=\"openRelatedGraphics\"><a href=\"#\" title=\"TABLES\">TABLES</a></div><ul><li><a href=\"image.htm?imageKey=DRUG/57469\" class=\"graphic graphic_table\">- Lexicomp clinical abbreviations</a></li></ul></li></ul></div></div><div><h2>RELATED TOPICS</h2><div id=\"outlineTopics\"><ul><li><a href=\"topic.htm?path=rifaximin-drug-information\" class=\"drug drug_general\">Rifaximin: Drug information</a></li><li><a href=\"topic.htm?path=rifaximin-patient-drug-information\" class=\"drug drug_patient\">Rifaximin: Patient drug information</a></li></ul></div></div>","javascript":null}